+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 102 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.

Age: 18Years +All GendersPhase 3
331 locations
E

Actively Recruiting

Researchers are evaluating the effects of enicepatide, a dual GLP-1GIP receptor agonist, for weight management in adults who have obesity or overweight with at least one related health condition, but do not have Type 2 diabetes. The study is a phase III, randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy of multiple doses of enicepatide compared with placebo. Participants will be randomly assigned to receive one of several dosing regimens of enicepatide or a placebo, administered once weekly using an integrated drug-device combination product. The treatment period lasts for 72 weeks, during which participants will self-administer the injections or receive assistance if needed. The placebo is volume-matched to the active drug to maintain blinding. Throughout the study, participants will have their body weight and other health measures evaluated regularly. Assessments include changes in waist circumference, blood glucose, insulin, cholesterol levels, blood pressure, and health-related quality of life. Safety is monitored by tracking adverse events and questionnaires related to mental health. The primary outcome is the percentage change in body weight from baseline to week 72, and the total participation duration covers this entire period.

Age: 18Years +All GendersPhase 3
209 locations
S

Actively Recruiting

This trial studies adults aged 50 to under 80 with mild or moderate calcific aortic valve stenosis and elevated lipoproteina levels. Researchers are assessing the safety, tolerability, and ability of pelacarsen TQJ230 given once monthly by injection to slow the progression of this heart valve condition. The study compares pelacarsen to a placebo in a randomized, double-blind design. Participants receive either pelacarsen 80 mg or a matching placebo as a subcutaneous injection monthly. They continue treatment and monitoring for up to 36 months to observe changes in heart valve narrowing and calcium buildup. The study also tracks lipoproteina levels and clinical heart-related events during this period. Throughout the study, participants will have regular assessments including imaging to measure aortic valve function and calcium score, blood tests for lipoproteina, and monitoring for safety. The main outcomes analyzed after 36 months include changes in valve jet velocity and calcium score, alongside clinical events. Participants remain under medical care while being observed for any effects of the study drug or placebo.

Age: 50Years - 80YearsAll GendersPhase 2
140 locations
S

Actively Recruiting

Researchers are evaluating invobenitug, also known as procizumab, in people with cardiogenic shock CS, a serious condition where the heart cannot pump enough blood to vital organs. This Phase 1b2a trial aims to study the safety, tolerability, and early effectiveness of this monoclonal antibody, while also understanding how the drug behaves in the body. The study focuses on patients who have high levels of circulating dipeptidyl peptidase 3 cDPP3 and require ongoing support for blood pressure and heart function. Participants are randomly assigned to receive either invobenitug or a placebo. The dose of invobenitug is 10 mg per kg of body weight. The trial is designed as a multi-center, double-blind, placebo-controlled study to carefully compare the effects of the drug against placebo. Treatments are given under close medical supervision, with researchers monitoring how the drug affects cDPP3 levels and activity to help determine the best dose for future studies. Throughout the study, participants are closely observed for any adverse effects from the treatment for up to 30 days after receiving invobenitug. Researchers measure the number of treatment-related side effects and track how the drug is processed in the blood over time. They also assess changes in cDPP3 concentration and activity. The study collects detailed safety and laboratory data to understand how the drug works and to ensure participant safety during the trial period, which lasts until the last follow-up visit at around 30 days after treatment.

Age: 18Years - 80YearsAll GendersPhase 1Phase 2
37 locations
S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
E

Actively Recruiting

Researchers are evaluating two imaging strategies to improve the treatment of patients with significant calcified coronary artery disease undergoing percutaneous coronary intervention PCI. The study compares a non-invasive coronary CT angiography CCTA-guided calcium modification approach with the current standard intravascular ultrasound IVUS-guided PCI to see if CCTA can enhance procedural efficiency and outcomes while maintaining similar safety. This prospective, multicenter, randomized controlled trial involves 700 patients with flow-limiting stenosis and moderate-to-severe calcification. Participants are randomly assigned to one of two groups one uses CCTA-guided calcium modification, which applies advanced CT imaging to plan and select plaque modification techniques before PCI the other uses IVUS-guided calcium modification following established intravascular ultrasound criteria for plaque preparation and stent optimization. Both groups receive post-procedural IVUS to confirm correct stent implantation. The study measures superiority in final minimal stent area and non-inferiority in 12-month target vessel failure. During the study, participants undergo pre-procedural imaging with either CT or IVUS to assess lesion characteristics. Researchers will evaluate procedure time, radiation exposure, contrast volume, stent area measurements, number of calcium fractures, and clinical safety outcomes including myocardial infarction and stent thrombosis. Patient-reported angina symptoms will also be tracked. The trial continues with follow-up assessments for 12 months to monitor clinical outcomes and safety, with the total participation lasting up to one year post-procedure.

Age: 18Years - 85YearsAll GendersPhase Not Applicable
15 locations
E

Actively Recruiting

Researchers are evaluating the Passeo-18 Lux paclitaxel-releasing percutaneous transluminal angioplasty PTA balloon catheter for treating new or recurring cholesterol-related blockages in the arteries of the lower leg. This device has been previously studied for safety and effectiveness and is approved for use in Europe, meeting European Union safety and performance standards. The trial focuses on gathering additional information about its performance and safety in everyday medical care, especially for longer balloon lengths. All participants in this single-group trial will receive treatment with the Passeo-18 Lux drug-coated balloon, which is available in various sizes. The treatment involves using this balloon catheter during angioplasty to address lesions in the infrainguinal arteries. The study will observe how well the device delivers, inflates, deflates, and is retrieved during the procedure, and will monitor lesion restoration after treatment. Participants will be followed for up to 12 months after the procedure to assess freedom from clinically-driven target lesion revascularization and major adverse events. Additional follow-ups will continue up to 60 months to monitor outcomes like survival without amputation, quality of life changes, walking ability, and lesion patency. Various clinical assessments, questionnaires, and angiograms will be conducted during scheduled visits to evaluate safety and effectiveness over time.

Age: 18Years - 99YearsAll GendersPhase Not Applicable
4 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of divarasib combined with pembrolizumab compared with pembrolizumab plus pemetrexed and carboplatin or cisplatin for adults with KRAS G12C-mutated, advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have not received prior treatment. This phase 3 randomized study aims to find the best first-line therapy option for this specific lung cancer type. Participants are randomly assigned to one of two groups one group receives divarasib orally once daily and pembrolizumab through intravenous infusion every three weeks, while the other group receives pembrolizumab, pemetrexed, and carboplatin or cisplatin all by intravenous infusion every three weeks. The study treatments are given as first-line therapy, and participants are monitored for up to approximately five years. During the study, participants undergo regular assessments including scans to measure tumor response, evaluations of lung cancer symptoms like cough and breathlessness, quality of life questionnaires, and monitoring for side effects. Researchers track progression-free survival and overall survival for up to about five years. Safety and symptom severity are closely followed throughout the study, providing comprehensive data on treatment impact and participant well-being.

Age: 18Years +All GendersPhase 3
288 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the Dual Energy THERMOCOOL SMARTTOUCH SF DE STSF catheter used with the TRUPULSE generator for treating ventricular arrhythmias, which are abnormal heart rhythms. This study focuses on whether the catheter and generator system can successfully treat these arrhythmias while following a specific procedural workflow during cardiac ablation. Participant safety is also closely monitored after the procedure to check for any complications. Participants with premature ventricular complexes PVC, sustained monomorphic ischemic ventricular tachycardia SMIVT, or sustained monomorphic non-ischemic ventricular tachycardia SMNIVT will undergo catheter ablation using the DE STSF catheter and TRUPULSE generator. The treatment involves delivering radiofrequency and pulsed field energy primarily as stacking applications, following the studys procedural workflow. This is a single-group interventional study assessing the catheter and generator combination. During the study, participants will be monitored for effectiveness at 3 months for PVC and at 6 months for SMIVT and SMNIVT after the ablation procedure. Safety monitoring includes checking for primary adverse events up to 7 days post-procedure and serious adverse device effects and other adverse events up to 6 months. Various intraoperative measurements such as procedure time, mapping, ablation parameters, and anesthesia type will also be recorded. Overall, participants will be followed until the primary completion date, which is up to about 15 months from study start.

Age: 18Years +All GendersPhase Not Applicable
6 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of JNJ-78934804 compared to guselkumab in adults with moderately to severely active Crohns disease, a long-term and progressive intestinal condition. This Phase 3 study aims to assess how well these treatments work by measuring clinical and endoscopic remission at Week 48. The study is sponsored by Janssen Research & Development, LLC. Participants are randomly assigned to receive either JNJ-78934804 or guselkumab, both given as subcutaneous injections. Treatment starts with induction doses at Weeks 0, 4, and 8, followed by maintenance doses every 4 weeks from Week 12 onward. Those meeting rescue criteria during the study may receive additional induction doses of JNJ-78934804 at Weeks 16, 20, and 24, then continue maintenance dosing from Week 28. After completing the double-blind phase at Week 48, participants who may benefit can join a long-term extension phase. During the study, participants will undergo assessments to measure clinical remission, endoscopic remission, and other outcomes like deep remission and corticosteroid-free remission at various time points. Researchers will monitor patient-reported outcomes, adverse events, and serious adverse events for up to approximately three years. The study involves regular evaluations of disease activity and safety to understand treatment effects and participant well-being over time.

Age: 18Years +All GendersPhase 3
287 locations

1-10 of 102

1